|
|
Article: CombinatoRx Stock Trading Halted Today; FDA Advisory Committees Meet to Discuss Exalgo.
- Article from:
- Business Wire
- Article date:
- September 23, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. & VANCOUVER -- CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company's common stock today. The U.S. Food and Drug Administration's (FDA) Anesthetics and Life Support Advisory Committee and its Drug Safety and Risk Management Advisory Committee are meeting today, in a public session, to review and discuss the New Drug Application (NDA) of Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, for Exalgo[TM] (hydromorphone HCI extended release) tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an ...